Ph1 ALL: Imatinib grows older with patients

Abstract

In this issue of Blood, Fielding et al demonstrate a significant enhancement of long-term outcomes for a large series of adult patients with Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL), who were prospectively treated in 2 sequential cohorts with an imatinib-containing protocol. © 2014 by The American Society of Hematology.